Ernest A Moore

US Patent:

20230068460, Mar 2, 2023

Filed:

Feb 4, 2021

Appl. No.:

17/797663

Inventors:

- Denver CO, US
Ernest Moore - Denver CO, US

International Classification:

A61K 38/17
A61K 38/48
A61P 7/02

Abstract:

Curative and prophylactic therapies for microvascular and/or macrovascular thrombosis are provided, as are prophylactic therapies capable of preventing fibrinolysis shutdown and therapies for non-thrombotic disorders. Methods provide for administering a therapeutically effective amount of an annexin A2.

US Patent:

20200208194, Jul 2, 2020

Filed:

May 11, 2018

Appl. No.:

16/612569

Inventors:

- Cambridge MA, US
- Denver CO, US
Ernest Moore - Denver CO, US
Hunter Moore - Denver CO, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
University of Colorado - Denver CO

International Classification:

C12Q 1/56
G01N 33/49
G01N 33/86

Abstract:

Coagulation and fibrinolysis assays and related compositions, systems, methods, and kits are provided. In some embodiments, a coagulation and fibrinolysis assay may utilize one or more biological molecules. For instance, the assay may comprise combining a blood or blood-derived patient sample with the biological molecule(s) and measuring one or more properties of the sample associated with coagulation and/or fibrinolysis. The biological molecules may serve to shorten the assay duration and/or enhance the sensitivity of the assay relative to certain conventional assays. In certain embodiments, the biological molecules may allow pathological coagulation and/or fibrinolysis phenotypes to be elucidated. The coagulation and fibrinolysis assays described herein may be used for a wide variety of clinical and/or laboratory applications, including the diagnosis of certain coagulation and/or fibrinolysis disorders, such as trauma-induced coagulopathy and hyperfibrinolysis.

US Patent:

20180177180, Jun 28, 2018

Filed:

Jun 8, 2016

Appl. No.:

15/580980

Inventors:

- Denver CO, US
Ernest MOORE - Denver CO, US

International Classification:

A01N 1/02
A61K 35/16
A61M 1/02

Abstract:

Systems for controlled freezing, storing and thawing a biological material in a bag and supporting apparatus. The systems are adapted to receive the biological material therein for freezing, storing, transporting and rapid thawing immediately prior to administration to a patient in need of the biological material.

US Patent:

20170336423, Nov 23, 2017

Filed:

Nov 5, 2015

Appl. No.:

15/524095

Inventors:

- Denver CO, US
Hunter B. Moore - Denver CO, US
Eduardo Gonzalez Barreda - Denver CO, US
Ernest E. Moore - Denver CO, US

Assignee:

The Regents of the University of Colorado, a body corporate - Denver CO

International Classification:

G01N 33/86
A61K 38/36
C12Q 1/56

Abstract:

In some embodiments, the invention provides methods for detecting an aberrant fibrinolysis condition in a patient. The method includes subjecting a blood sample from the patient to a viscoelastic analysis in the presence of a known amount of a thrombolytic agent, to obtain a coagulation characteristic value of the patient; and comparing the coagulation characteristic value of the patient to a coagulation characteristic value of a healthy individual, the coagulation characteristic value of the healthy individual obtained by subjecting a blood sample from a healthy individual to the viscoelastic analysis in the presence of the known amount of the thrombolytic agent, wherein a difference in the coagulation characteristic value of the patient as compared to the coagulation characteristic value of the healthy individual identifies the patent as having aberrant fibrinolysis. In some embodiments, the invention also provides a container adapted for detecting an aberrant fibrinolysis condition in a blood sample using viscoelastic analysis comprising an interior having a coating comprising a thrombolytic agent.